The Phase 3 EPCORE DLBCL-2 trial showed that adding epcoritamab, a bispecific antibody, to standard R-CHOP therapy significantly improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients with intermediate to high risk. The combination reduced the risk of disease progression or death by 51% compared to R-CHOP alone, marking a potential new frontline standard of care. The safety profile was consistent with known effects of the drugs. AbbVie and Genmab plan to engage global regulators for approval and will present detailed data at future medical meetings.
AbbVie shares are trading at USD 264.72 with a 0.72% gain as of Oct 06, 2026 02:03 WIB on Pluang, reflecting steady investor interest alongside the promising trial results for epcoritamab in combination with R-CHOP. The stock remains close to its 52-week high of USD 266.40, supported by a strong market cap of $464.43 billion and a dividend yield of 2.63%. This positive market activity coincides with AbbVie and Genmab's plans to seek regulatory approval for this potential new frontline treatment for diffuse large B-cell lymphoma.
AbbVie announced that RINVOQ (upadacitinib) demonstrated sustained facial and total body repigmentation in non-segmental vitiligo patients through 76 weeks in Phase 3 Viti-Up-1 and Viti-Up-2 studies. The data, presented at the 2026 EADV Congress, als...
Five dividend-paying stocks from consumer staples, financials, real estate, and healthcare sectors—Coca-Cola, PepsiCo, JPMorgan Chase, Realty Income, and AbbVie—are highlighted for their strong cash flow and consistent dividend growth. Each company c...
AbbVie will announce its third-quarter 2026 financial results on October 30, 2026, before the market opens. The company will host a live webcast of the earnings call at 8 a.m. Central time, accessible via its Investor Relations website. This event is...
